|  |  | 

India Top Headlines

Sufficient stock of Covid-19 vaccine for inoculation of priority groups in the first phase: Niti Aayog member, VK Paul | India News


NEW DELHI: India has sufficient stocks of the Covid-19 vaccine for inoculation of priority groups, including healthcare workers and frontline workers, in the first phase, VK Paul, a member of Niti Aayog, said on Monday.
Paul, who is also chair of the National Group of Experts on the Administration of Vaccines for Covid-19 (NEGVAC) further said that the government will soon announce its plans for the purchase and distribution of the Covid-19 vaccine.
“Our first phase (of vaccination) comprises priority groups at high risk of mortality and our healthcare and front-line workers. For them, we believe we have enough stock (Covid-19 vaccine),” he told PTI in an interview.
India’s drug regulator DCGI on Sunday approved the Oxford Covid-19 Covishield vaccine, made by the Serum Institute, and indigenously developed Bharat Biotech’s Covaxin for emergency restricted use in the country, paving the way for a mass inoculation campaign.
Paul noted that “within three or four months, there will be other vaccines and the stock will be even greater.” And more acceleration can be achieved in the vaccination program, “added Paul.
When asked when the government will announce its plans for the purchase and distribution of the Covid-19 vaccine, he said, “This will continue. Now that the essentials have happened, all these steps will be taken.”
When asked what the biggest challenge would be in mass vaccination for Covid-19, Paul noted that the biggest challenge encompasses the great mobilization that is required for such an effort.
“Well, the most important challenge for mass vaccination on such a scale is mobilizing beneficiaries on the designated day and conducting sessions on fluid systemic protocols, ensuring proper Covid-19 precautions, I think is the biggest challenge,” he observed. .
According to Paul, the purpose of vaccination is a staggered ambition and can be considered hierarchical.
“Ultimately, we would like vaccination to stop, paralyze and extinguish the pandemic, that is the ultimate purpose,” he said, adding that to achieve this, a herd immunity of around 70 percent must be created, either through vaccination. or by vaccination. adding those people who have suffered a natural infection.
Paul noted that for normal life to continue, there must be enough vaccinated people, so that the country’s industry, schools, transportation, judicial system, and parliamentary activity continue.
“Although the virus may be there, the pandemic may not be over, but enough economic and social life could continue,” he stressed.
Answering a question India doesn’t have experience On adult vaccination, Niti member Aayog noted that countries face new challenges and then respond based on their intrinsic capacity.
“We have a great deal of experience in running immunization programs. We have experience in managing matters like national elections that are held over a short period of time across the country,” he said.
“So those experiences and those SOPs will be useful and will build on the ingenuity of India, the innovation of India and the experience of India that will allow us to put together a successful vaccination program, even if it is unprecedented,” he added.
Referring to the ‘Covid-19 Vaccine Operational Guidelines’ recently issued by the health ministry, Paul said: “God forbid, if you have any comorbidity, you will receive a vaccine in the first phase of the vaccination program. Otherwise You will receive after these high priority groups have been covered. ”
India’s drug regulator DCGI on Sunday approved the Oxford Covid-19 Covishield vaccine, made by the Serum Institute, and locally developed Bharat Biotech’s Covaxin for restricted emergency use in the country.
The approval by the Comptroller General of Medicines of India (DCGI) was granted based on the recommendations put forward by a Covid-19 subject matter expert committee (SEC) of the Central Medicines Control Organization (CDSCO) .
“After proper review, CDSCO has decided to accept the Expert Committee’s recommendations and consequently the M / s Serum and M / s Bharat Biotech vaccines are being approved for restricted use in emergency situations,” said Dr. VG Somani from DCGI.
This paves the way for the launch of at least two vaccines in India in the coming days.
The Serum Institute of India, the world’s largest vaccine manufacturer, has partnered with AstraZeneca to manufacture Covishield.
Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council for Medical Research (ICMR).
In addition, the authority granted Cadila Healthcare permission to conduct the phase III clinical trial of its candidate vaccine in India, Somani said.

Original source